Sotera Health Company

Good morning. My name is Denise and I will be your conference call operator today. At this time, I would like to welcome everyone to the Sotera Health Q3 2022 earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remark, there will be a question and answer session. If you would like to ask a question during that time, please press star one one on your telephone and wait for your name to be announced. I will now and the call over to Jason Peterson, Vice President and Treasurer.

Good morning and thank you. Welcome to Cetera Health's third quarter 2022 results call. You can find today's press release and accompanying supplemental slides in the investor section of our website at ceterahealth.com. This webcast is being recorded and a replay will be available in the investor section of the Cetera Health website. On the call with me today are Chairman and Chief Executive Officer Michael Petras and Interim Chief Financial Officer Michael Biel. During the call, some of the statements the company makes may be considered forward-looking statements. The matters addressed in these statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected or implied. Please refer to the TerraHealth SEC filings in the forward-looking statement slide at the beginning of its presentation for description of these risks and uncertainties. The company assumes no obligation to update any such forward-looking statements. Please note that during the discussion today, the company will present both GAAP and non-GAAP financial measures, including a just EBITDA, a just EPS, net debt, net leverage ratio, and constant currency comparisons. A reconciliation of GAAP to non-GAAP measures for all relevant periods may be found in the schedules attached to the company's press release and in supplemental slides. The operator will be assisting with the Q&A portion of the call today. Please limit yourself to one question and one follow-up so that we can try and give everyone an opportunity to ask questions. I will now turn the call over to Sotero Health Chairman and CEO, Michael Petras.

Good morning, everyone, and welcome to Sotero Health's third quarter 2022 earnings call. I'm pleased this morning to be reporting another quarter of year-over-year top and bottom line growth This marks the eighth consecutive quarter of top and bottom line growth since we began reporting as a public company. Our team has done a good job executing considering the macroeconomic environment that we're experiencing. Although we see some improvement in certain areas of the broader macro environment, other areas remain choppy, which makes delivering consistent growth that much more of a challenge and an accomplishment. I would like to thank the Satara Health team for living our values each and every day. As long as we focus on executing against our strategy, serving our customers, and remaining committed to our values, I am confident that we will continue to perform. Michael Beal will provide more detail on our financial results in a moment, but first I want to highlight a few items from our third quarter results. We reported total revenue growth of 10% and adjusted EBITDA growth of 7.3% compared to the third quarter of 2021. On a constant currency basis, revenue grew by 13.2% as FX continues to remain a significant headwind. We delivered adjusted EPS of 23 cents for the quarter, which is a 2 cent increase over the same period last year. Compared to the first nine months of 2021, year-to-date revenue grew by 9%, which equates to 11.3% growth on a constant currency basis. Let me now shift to cover what we're experiencing across the businesses. Sterigenics, our largest reporting segment, operationally delivered in another strong quarter as the team continues to work to offset inflation pressures being felt around the globe. The segment is seeing solid demand across all major modalities in both medical device and bioprocessing products. On a year-to-date basis, Sterigenics has delivered both top and bottom line double-digit growth which is a testament to the strength of the business model. Sterigenics continues to make progress on its capacity expansion programs and facility enhancements. We have now completed three expansions in 2022, including our recent move to a state-of-the-art EO facility in Canada to help meet growing customer demand. The remaining seven active capacity expansions which includes two green fields, are expected to come online at various points over the next 24 months or so. We also continue to make solid progress on the EO emission control enhancements we're making across our U.S. network. An additional facility was completed during the quarter. These industry-leading investments mark our ongoing commitment to maintain best-in-class operations for our employees, customers, and the communities in which we operate. norian our other reporting segment within the sterilization services business continues to have a strong year as demonstrated by double digit top and bottom line growth in both the third quarter and on a year-to-date basis as i've highlighted throughout the year the norian team has done an exceptional job successfully navigating a difficult geopolitical environment to mitigate the risk of cobalt 60 shipments in 2022 at this point in the year we have completely de-risked any disruption of Russian supply for 2022. As we have mentioned in the past, the timing of Norion's revenues are lumpy due to the timing of nuclear reactor supply schedules. Although we expect the remainder of 2022 to play out as previously communicated, we expect to see continued lumpiness in the future during 2023. Nelson Labs, our lab testing advisory service business, grew revenue by over 7% versus the third quarter of 21. Although we are pleased with the Nelson Labs growth compared to their prior year quarter, the demand recovery for certain testing services has been slower than expected. We have seen some areas of testing perform well, while others have not ramped up as quickly. Over the past two quarters, Nelson Labs increased staffing in anticipation of incremental volumes. Unfortunately, we have not seen a strong increase in demand for certain testing services, which has resulted in some pressure on margins. However, the more stabilized staffing levels have resulted in improved customer service metrics and overall customer satisfaction scores. I also want to note that experts required for this type of work are challenging to find, and we are fortunate at Nelson Labs that we've been able to retain our high-caliber talent. We feel confident Nelson Labs is positioned well to take on incremental demand as customers continue to work through the macroeconomic headwinds that exist. Today, with three quarters of the year complete and good visibility in the year end, we're adjusting our full year 2022 outlook, taking into consideration the macroeconomic pressures I've mentioned, as well as the solar recovery at Nelson Labs. Therefore, we expect our full-year net revenue growth to be 7% to 8%, while our full-year adjusted EBITDA to grow 4% to 6%. We have also narrowed our capital expenditures range to $150 million to $170 million for the year. We continue to feel very good about the growth prospects of Cetera Health. Our strategy has not changed, and we are executing for growth over the long term. We play a critical role in safeguarding global health in our service Our services are necessities for many healthcare companies. Before I turn the call over to Michael Beale, I want to highlight some recent examples of how we deliver on our mission, safeguarding global health. One area of testing I'd like to highlight is our extractables and leachables testing, referred to as ENL testing. This testing is required for both medical device and pharma products. Nelson Labs has a leading position in this growing test segment. This mission-critical analytical chemistry testing identifies the presence of potentially harmful compounds that could be present in drug delivery in container closure systems. The medical device extractables testing is evaluating the potential biological hazards that a patient could experience with use of the product. One example of this testing is the toxological evaluations of feeding tubes used for neonatal patients. Nelson Labs performs these evaluations to identify compounds that would be at unsafe levels for babies. The Nelson Labs team then works with the customer to remediate any issues to ensure safe uses in the future. The E&L testing is largely done in our Leuven, Belgium location, serving global customers. This is just another example of how Nelson Labs is working to better service our customers and safeguarding global health. At Sterigenics, one of our EO facilities sterilizes the only approved interventional cardiac replacement system for patients with a severe dual diagnosis of aortic stenosis and aortic regurgitation. The U.S. FDA and the Canadian Ministry of Health are using these medical devices through their humanitarian assistance programs to save patients' lives. We are proud to once again share these examples of how our Satara Health team is working to ensure healthcare is consistently, reliably, and safely delivered every day. Now, Michael will be able to take us through the financials in more depth. Thank you, Michael.

I'll first cover the third quarter 2022, highlights on a consolidated basis, and then provide some details in each of the business segments, along with updates on capital deployment and leverage. I'll conclude with some additional details around our update for the 2022 outlook. On a consolidated total company basis, revenue grew by 10% as compared to the third quarter of last year to $249 million. This equates to 13% growth on a constant currency basis. Just at EBITDA grew by 7.3% from the third quarter of 2021 to $125 million. Adjusted EBITDA margins were 50.3%, representing 127 basis point decline from the third quarter 2021 levels. The adjusted EBITDA margin decline compared to third quarter 2021 was driven primarily by the following items. First, an unfavorable impact at Nelson Labs from increased staffing and anticipation of incremental volumes as well as lower margins due to some of our recent acquisitions as they integrate into the overall company. And second, the timing of pricing actions versus realized inflation at Sterigenics. Both of these were partially offset by favorable volume, mix, and pricing at Nordion. Our operating performance drove adjusted earnings per share of 23 cents, an increase of 2 cents from third quarter of 2021. The looted EPS for the third quarter 2022 was $0.09, which was a $0.01 decline from the third quarter of last year. A reported interest expense of $23 million is burdened by mark-to-market loss on certain outstanding interest rate hedges for which we did not elect hedge accounting. We have removed the effect of that loss in our adjusted earnings per share. Excluding this loss, Q3 interest expense was approximately $20 million. Now let's take a closer look at our segment performances. In the third quarter, Sterigenics operationally delivered another strong quarter with 9% revenue growth to $158 million and an 8% segment income growth to $86 million as compared to the third quarter of last year. On a constant currency basis, Sterigenics grew revenues 12% and segment income 11% compared to the third quarter of last year. Revenue growth drivers for the third quarter included favorable pricing of 6% and favorable volume and mix of almost 6%, partially offset by unfavorable foreign currency headwinds of 3.3%. Compared to the third quarter of 2021, segment income margins contracted by 30 basis points to 54.3%, driven by the timing of contractual pricing actions versus realized inflation. Sequentially, margins did improve over the second quarter 2022 levels. As Michael mentioned, we are seeing solid demand across all modalities as our customers continue to rely on Sterigenics mission-critical services. Nordion had strong third quarter with revenue growing by 22% to approximately $35 million compared to the third quarter of 2021. Nordion's segment income grew by more than 24% to $20 million compared to the same period last year. On a constant currency basis, Nordion grew revenues 25% and segment income 27%, compared to the third quarter of last year. Nordion's revenue growth was driven by volume and mixed growth of nearly 18%, pricing of 7%, which was offset by 2.8% foreign currency exchange headwinds for the quarter. The outsized growth Nordion experienced versus the third quarter of 2021 is representative of the previously noted lumpiness related to the timing of nuclear reactor supply schedules. Nordion's margins were 57.9%, 110 basis point improvement from Q3 2021 margin levels. Increased margin levels were a result of increased volume, more optimal product mix, and pricing. For Nelson Labs, The third quarter of 2022 revenue improved 7.3% to $56 million compared to the third quarter of 2021. Segment income of $19 million was 8% unfavorable versus Q3 2021. On a constant currency basis, Nelson Labs grew revenues 11% while segment income declined by 4% compared to the third quarter of last year. Revenue growth for the third quarter of 2022 was impacted by a 6.3% benefit from pricing and nearly a 6% increase from our recent acquisition. Those benefits were partially offset by foreign currency exchange headwinds of 3.5%. Q3 2022 margins for Nelson Labs contracted to 34.5%, or approximately 580 basis points versus Q3 2021 margin levels. This decline was driven by increased staffing and anticipation of incremental volumes, which we now expect to continue in the fourth quarter. In addition, dilution from recent acquisitions and unfavorable revenue mix impacted the third quarter, partially offset by favorable pricing. These trends are reflected in our revised 2022 outlook provided today. Prior to providing highlights related to capital deployment and net leverage, I'd like to touch on cash generation. So, Terra Health is proud to deliver mission-critical services to the healthcare industry through its sterilization and lab testing services. Because of the important services we offer and the strength of our business model, we have generated between $50 and $70 million of operating cash flow each quarter during 2022. This allows us to fund operating needs and invest for future growth, all from operating cash flow. As of September 30, 2022, we had $165 million in cash and over $440 million in available liquidity. Our net leverage fell to 3.3 times adjusted EBITDA for the quarter. Our CapEx for third quarter of 2022 was $39 million, consistent with the increased levels of spend that we communicated for a full year 2022. Growth CapEx and facility enhancements continue to drive our increased investment levels and we are in track to invest 150 to 170 million into the business in 2022. Now I'd like to recap our update for the full year 2022 outlook, which reflects the trends that we are seeing and believe will continue to impact the remaining months. For the full year 2022, we have adjusted total net revenues to the range of 995 million to 1.005 billion, representing annual growth of approximately 7% to 8%. We have adjusted our adjusted EBITDA range to 500 million to 510 million, representing annual growth of approximately 4% to 6%. This guidance range incorporates an incremental 1% unfavorable foreign currency impact on top of what we communicated last quarter as well as slower recovery in certain testing categories at Nelson Labs. We have lowered our adjusted net income effective tax rate to approximately 28%. Adjusted EPS is now expected to be in a range of $0.91 to $0.95, reflecting the adjusted EBITDA flow through, as well as the change in the effective tax rate. Our current expectations are that net leverage will land in the range of 3.2 times to 3.3 times by the year end. Subject to any changes to our debt related to appellate bonding, which Michael will comment on further. The other elements of our previously issued outlook remain the same. I will now turn the call back over to you, Michael.

Thanks, Michael. Before we open it up for Q&A, I will provide an update on our EO litigation in Illinois, because I know many of you understandably have questions. In deference to the court system as the appropriate forum in which all parties and their lawyers ought to be addressing these complicated issues, I will not provide further comment beyond this briefing. As has been widely reported in the media, in September, the jury in the first EO trial, Cook County, Illinois, returned a verdict in favor of the plaintiff, Susan Kamuda, and awarded her compensatory damages, punitive damages, and prejudgment interest in the amount of $358.7 million against our subsidiaries, Sterigenics US LLC and Saterra Health LLC. Sterigenics US operates EO and gamma sterilization facilities in the United States. Cetera Health LLC is the holding company of Sterigenics US and a subsidiary of Cetera Health Company. We do not believe the facts, the signs, or the law justify the verdict or damage awards, and we intend to vigorously challenge them through all appropriate motions for post-trial relief and appeals. On October 25th, we began that process by filing a motion for post-trial relief with the trial court. The motion for post-trial relief addresses both the verdict and the damages awarded. First, the motion for post-trial relief asks the court to enter judgment in favor or in the alternative to grant a new trial. The basis for this request for relief includes the insufficiency of the evidence at trial to support the verdict, numerous errors in the trial court's rulings on important motions, and about the admissibility of evidence in numerous errors in the court's instructions to the jury. Second, the motion proposed trial relief asked the trial court to reduce the compensatory damages on the grounds that the award was excessive and not supported by the evidence. Third, the motion proposed trial relief requests the trial court to vacate or reduce the award of punitive damages on the grounds that the strict threshold standard for allowing a jury to award punitive damages was not met and that the jury's award was not supported by the evidence. While I will not go into the details, the motion for post-trial relief presents our arguments that there are no credible scientific studies suggesting, let alone establishing, that exposure to the levels of EO alleged by Mrs. Kamuda can or do cause cancer. Various rulings by the trial court improperly impeded our defense on this case, particularly on the lack of causation and otherwise resulted in unbalanced and unfair trial. The compensatory damages, which were nearly double the amount sought by the plaintiff's lawyers at trial, were excessive and fueled in significant part by evidence and argument that should not have been presented to the jury. The strict and high standard for awarding punitive damages was not met. and the punitive damage awards were entirely out of proportion to the alleged misconduct. The motion for post-trial relief and any subsequent appeals are expected to stay the enforceability of the Camuta judgment, including citations and liens that Mrs. Camuta's lawyers attached before the motion for post-trial relief was filed against Sterigenics US, Cetera Health LLC, our parent company, and many of our other subsidiaries. Obviously, these are the company's views of the verdict and the issues associated with the verdict. Mrs. Kamuda and her representatives have differing views. If our post-trial motions are not successful, we intend to take these serious issues up to the appellate courts. The range of loss for this case could be from $0 to $358.7 million plus potential post-judgment interest. However, the company does not believe that after rulings on all appropriate motions for post-trial relief and appeals, liability to the plaintiff is probable and thus no reserve has been recorded. If and when appeals prove necessary, Sterigenics US and Sotero Health LLC will be required to post a surety bond or other security pending the appeals. The amount of the bond will ultimately be determined by the courts and per the typical application of the governing rules to less atypical outcomes, could be as high as 150% of the judgment unless the trial or appellate courts determine a lower amount to be more just and appropriate under the totality of circumstances. We are working to secure the bond or other security and expect to be able to do so, but we will have to navigate the present state of the capital markets. Regarding the timelines for review of this first EO case, We are eager to proceed with the post trial proceedings as expeditiously as possible. However, it is difficult to predict with any degree of certainty the exact timelines. Motions and appeals can take months at minimum and at times require a year or more to resolve. The second EO trial is now underway before a different judge and a different jury in Cook County and is currently expected to conclude in mid-November. The third trial is scheduled to begin in January 2023, and a fourth trial is scheduled to begin in April 2023. These are individual plaintiff trials in which only the claims of each of the plaintiff's case will be litigated. These trial dates and the overall case management schedules will be determined by the courts in due change from time to time. Subject to change, we expect that the five Individual Illinois trials previously scheduled to begin in January 2023 will not be tried at that time. Furthermore, at a recent hearing, the court indicated the claims of small groups of plaintiffs should be tried jointly starting in late May 2023. The parties have been instructed to confer to identify plaintiffs whose claims could be tried jointly because the details of individual claims are similar. We will know more in mid-November about whether joint trials are possible and when they will be scheduled. But even if the joint trials proceed, they will remain individual actions. It will not become class actions by the virtue of this latest procedural development. And finally, as announced earlier today, we welcome seasoned executive and highly respected litigator Alex Dimitrieff to our executive team as general counsel. Alex grew up in Illinois. and was a litigator in the Chicago office of Kirkland and Ellis LLP for 20 years. Alex and I worked together when he left K&E to join GE, and Alex is a brilliant legal mind, a successful litigator, and champion of integrity with respect to law and justice. We welcome Alex's experience, input, and guidance regarding the EO cases. I want to reinforce several important points. Soterra Health respects the legal system and the rights of the plaintiffs to present their cases. But with respect, we regard the outcome of the first EO trial to be unjust and unsupported by the facts, the signs, or the law. We intend to continue to vigorously defend Sterigenics, US LLC, and Cetera Health LLC against these claims. Our company plays an indispensable role in healthcare. We conduct our operations with profound respect for our legal, regulatory, and other obligations, and our employees operate our facility safely, responsibly, and compliantly. It's our employees' commitments to our company, our mission, our customers, and the communities in which we operate that have driven Sotero Health's consistent and outstanding performance over so many years. It gives me so much optimism over our outlook for 2022 and beyond. At this point, Operator Denise, let's open the call for Q&A.

Thank you. We will now open the lines up for the question and answer portion of the call. If you would like to ask a question during that time, please press star one one on your telephone. Listen for your name to be announced. As a reminder, please limit yourself to one question and one follow up so that we can try and give everyone an opportunity to ask questions. Stand by while I compile the Q&A roster. Our first question comes from the line of Sean Dodge with RBC Capital Markets. Sean, your line is now open.

Sean Dodge Yep, thanks. Good morning. In Nelson, you mentioned one of the items Pressuring margins there in the quarter was increased staffing ahead of an anticipation of higher volumes. I guess if you could share a little bit more detail on that, what kind of visibility do you have on the volume increase that you're looking for there?

Yeah, good morning, Sean. Can you hear me okay? Because you were breaking up a little bit on your question, but I think I got the gist of it. Can you hear me okay? Yeah, I can hear you clear. So it was just... I got it. I think I got the question. It was on Nelson, not on Labor, I think is your question, right?

Yeah, in anticipation of higher volumes, the visibility you have on the volumes.

Yes. Thanks, Sean. So, you know, the visibility on the Nelson business isn't as great as it is on the other business. Obviously, Nordion has the most visibility out of the business units. Nelson has less visibility. As we mentioned, coming out of 21 and rolling into 22, the labor challenges, staffing challenges have been pretty pretty difficult. We've been able to stabilize that, but the volume just hasn't come through to the extent we want it. So we lost some productivity in the quarter, which put pressure on the margins. But overall, you know, the business is performing pretty well as we've referenced the net promoter score and the overall turnaround times and service has been much better.

Okay. And then staying on, Nelson, you mentioned a few things they're dragging on more. The increase in capital being one, the revenue makes you tremendous. foreign exchange. Can you give us an idea, maybe quantify the relative magnitude of those? Is it the staffing piece that's kind of the biggest drag or kind of impact on the Nelson Mortons right now?

Yeah, yes. It's the biggest drag is the labor productivity piece. And then you have, as we mentioned, some product mix in there as well. Currency's got some impact as well, but that's the biggest driver in that order. Okay. Great. Thank you for taking the question. Yeah, Sean, don't forget also embedded within that mix, you've got the protective barrier piece that's down 50% year over year, which was pretty high mix. Although, as we've stated, we're at more normalized levels now going forward, it's still in the quarter was down 50% from last year's same quarter.

Thank you. Please stand by for our next question. Our next question comes from the line of Patrick Donnelly with Citi. Go ahead. Your line is now open.

Jason on for Patrick. Maybe just one on Nordion. You mentioned you de-risked all of 2022 from a geopolitical standpoint, but there might be some lumpiness in 23. So how should we think about the potential risk there in sourcing cobalt from places like Russia maybe next year?

Yeah, Jason, thanks for the question. Yeah, as we referenced, you know, we feel confident where we stand with cobalt supply in 2022. We're not going to get into a lot of details on 2023. As we turn the quarter, we'll be able to give guidance in the total year and kind of how we see it. But, you know, From time to time, with any of our cobalt supply, we've got to work through challenging or different opportunities that present themselves during the course of the year. What we want to call out is it will be lumpy like it was this year. It's not a smooth, consistent harvest schedule from the reactors every single quarter. There will be variation in that. It could be significant at times, resulting in the word lumpiness, our new official word over at the Nordian side.

And then maybe one on litigation outside of Willowbrook. I guess just how should we be thinking about litigation go forward across some of the other various trials you have taking place here in the coming months?

Yeah, what I would tell you is, you know, those are all different various stages. process you know Georgia will have a case that will go to trial late next year and then the rest of the Georgia cases in New Mexico are going to be beyond 2024 on the litigation that you see similar to the Illinois litigation thank you thank you

Stand by for our next question. Our next question comes from the line of Phil Kuver with Goldman Sachs. Go ahead. Your line is now open.

Thanks for taking the questions. Appreciate it. One fundamental one and then one on facilities. So the first one, just looking for a little bit more clarity on the Nelson Lab side, I think the language was you know, limited recovery and then waiting for customer demand to reaccelerate. Just hoping you can give a little bit more color on kind of systemically what's still limiting recovery on the Nelson Lab side and then what you're looking for to change with regard to customer demand for it to reaccelerate.

Yeah, Phil, it's Michael. What I would say is we've seen, as you heard in the prepared remarks, we've seen some growth in the Nelson business. It just hasn't returned to the levels that we were hopeful that it would. We're seeing routine testing doing very well. We're seeing extractable and leachable testing, as I referenced in my remarks, doing very well. It's just some more of the validation, more complex testing that's been a little slower to recover. And that's really, you know, as we talk to our customers, they're a little slower in some of their development activities that would drive that. But overall, you know, we still feel optimistic about growth going forward in that business. It just hasn't been to the level that we were expecting here in the second half of the year.

Sorry to push, but just what's precipitating that slower recovery? Is it FDA timelines or what would you kind of pinpoint as why customer demand hasn't reaccelerated at the rates you would have anticipated?

I would just say some of the development with the customers on new products or requalifications of products has been a little slower. We have one particular customer that's having an issue with the FDA that they're working through that's causing some challenges as well. And so there's a little bit of uncertainty with the FDA, but then there's also some customer-specific activities that are driving that.

Okay. That was really helpful. Thanks. The second one, we noticed two notice of violations in Southern California plants that you guys operate. I'm wondering if you have any comment on the circumstances there and any disruption you've either seen so far or anticipate as a result of the communications with the local authority.

Thanks. No, we're working with South Coast. We've got two facilities in the LA area that are about next to each other and then one in Ontario. We continue to work with the regulators. In L.A., we have an agreed-upon process and plan going forward for the enhancements that we're rolling out throughout the United States. And in Ontario, we continue to have discussions with them. We continue to operate those facilities and serve our customers day in and day out with the millions of devices we sterilize there.

Okay. And right now, nothing that would indicate a legal risk in Southern California for either plant?

No, we continue to operate the facilities. There's always legal risk, as you know, but we continue to operate those facilities. We continue to take care of the customers, and we're running at full force in those facilities as we speak.

Okay. Thank you, Michael. Appreciate it.

Thank you. Yeah, Phil. Denise, are there any more questions in the queue? Denise, do you have any further questions? Sorry about that. I'm not hearing anything. Sorry about that. Okay.

Thank you. Our next question comes from Matt Michon with KeyBank. I apologize for that. Okay.

Okay, great. Thank you for taking the questions, Michael. Just a quick one, just to quantify the, let's call it, the change in guidance, looks like it's maybe 10 to 12, maybe 10 million at the midpoint, 10 to 11 million at the midpoint. Just how much of that is FX and how much of that is organic?

Yeah, Bob. This is Michael Beale. 60% of it is on the revenue side is impact, FX. And then roughly 40% on 20%, it's about 60% on FX and 20% FX on EBITDA.

Just two more, if I can squeeze them in. First, why is testing slow at Nelson? What's really driving that?

As I just referenced, Matt, with one of the previous questions, we're seeing more in the validation, the more complex testing. It's a result of customers not as moving along as fast in some new product development activities, as well as some regulatory challenges, either with the regulators themselves or just problems within the customers with some some challenges that they're facing. Those are two primary drivers. But the routine lot release is doing well. Extractable leachables is doing well. It's more around the validation, more complex testing.

And then last one, just bigger picture. I mean, as part of one of the drawbacks of litigation, you know, a lot of people have asked about what has changed in capital allocations And, and how you think about that over the next couple of years, just, you know, broadly how you're, how you're looking at, you know, capital allocation, um, and some of your investments as a result, as a result of some of the uncertainties.

Yeah. As, uh, we referenced earlier, you know, we had previous guidance, 140 to 170 of CapEx for the year based on the run rate of all the activities that we have in process. It looks like it's gonna be closer to 150 to 170. So we tighten that range. We are rolling up our plans for 23 as we get in the operating budgets for 23. We continue to invest in capacity expansions to meet our customers' demand and take care of the needs that they have. We'll be very thoughtful on how we do it. We're going to continue to look for opportunities to deleverage in the business and over long-term looking at M&A as well. So we go through a pretty rigorous process in how we evaluate capital and we'll continue to do that as we roll in the 23.

Thank you very much.

Thanks, Matt.

Thank you. We have one more, couple more questions. Our next question, please stand by. Our next question is from Michael Pollark with Wolf Research. Go ahead, your line is now open.

Hey, good morning. Thank you for taking the questions and appreciate the full update on the EO litigation matters. My question on that topic is bigger picture. You know, the initial commuter verdict was high profile. It was a higher than expected number. What do you hear from your customers on the heels of this? I mean, obviously the system hasn't figured out a better way, you know, to do this critical work. And, you know, I'd just be curious, you know, kind of the tone and tenor of the conversations with important customers on the heels of this outcome.

You know, Mike, with the backdrop that 50%, according to the FDA, 50% of medical devices in the U.S. are sterilized with EO or over 20 billion devices a year. It's a critical sterile with no alternatives out there. The customers recognize that. They've got broader concerns when they see how this was handled in the courts. But they continue to support this business, continue to rely upon Sterigenics. You see Sterigenics had a very solid quarter, continue to grow. It's had a great year. So our customers have been very supportive in understanding the critical role that Sterigenics plays day in and day out. And we're working to do the best that we can to continue to meet their needs as we go ahead and put these improvements in and wait to navigate through this regulatory uncertainty. We're still hopeful that we get a new rule here from the EPA on these rules. And that's the same thing that the broader industry is waiting for. Right now, it looks like that probably won't come until 2023. So I would say the customer has been very supportive. We continue to see robust demand and interest in how we could fill their needs.

And then my follow up is just a small picture numbers question. The tweak to the leverage reduction target this year from a half a turn to call it a quarter turn? I mean, the change to EBITDA, as far as I'm doing the math, doesn't explain all that. So can you just walk me through kind of what drove the fine-tuning of the slightly more modest leverage reduction goal this year?

It's really based upon the reduction of EBITDA for the year. That's the primary driver.

Okay. All right. Thank you very much.

Thanks, Mike.

Thank you.

Thank you. Looks like we have a follow-up question. Our next question comes from Phil Hoover with Goldman Sachs. Welcome back. Your line is now open.

Okay. Did you see any other questions? Yes, there we are, Phil. Yes, I can hear you.

Go ahead.

Phil Hoover from Goldman Sachs. Thank you. Hey, Phil.

Hi. Thanks. Just a quick one on FX. Other companies have been amenable to giving a preliminary kind of estimate for 23 from FX with currencies having impacted the quarters. Just wondering if you can give a comment on top line and potential EPS or EBITDA headwind right now that you're projecting for 23 from currency. Thanks.

No, Phil, we're not prepared at this time to give comments on 23 regarding FX.

Okay, fair enough. Thanks for taking the follow-up.

Great. Okay, Denise, any further questions?

At this time, no more further questions. I'd like to turn the call back over to Michael Petras for closing remarks.

Yeah, great. Thank you, Denise. Thank you, everybody, for taking the time this morning. I know the prepared remarks were a little bit longer, but we felt that it was important. You folks had several questions. We wanted to make sure that we were able to address those up front. So thanks for your time. Appreciate your continued support of Cetera Health. And as you can see, we're really proud of what this team's doing. They had another solid quarter. And we look forward to rounding out 22 and then being able to talk to you about 23. So thanks for all your ongoing support and have a great day. Bye-bye.

Thank you for your participation in today's conference. This does conclude the program. You may now disconnect.